Studies of the coagulation and fibrinolytic systems in hyperstimulation syndrome after administration of human gonadotropins.
Coagulation and fibrinolytic profiles have been studied in two groups of sterility patients receiving low dosage regimens of human gonadotropins for ovarian stimulation. This investigation was prompted by a report of two patients with severe episodes of intravascular coagulation associated with periods of "hyperstimulation" from these drugs. No statistically significant changes were found as a result of administration of one ampoule of human menopausal (HMG) or pituitary gonadotropins (HPG) for 8 days followed by 9000 units of human chorionic gonadotrophin (HCG). A course of 2-3 ampoules HMG on alternate days for longer periods of time prior to administration of HCG also failed to produce significant alterations of the coagulation or fibrinolytic mechanisms. In two patients with severe hyperstimulation there were elevated levels of factor V, platelets, fibrinogen, profibrinolysin, and fibrinolytic inhibitors. Generation of thromboplastin was also increased when plasma was diluted one to fifty in the thromboplastin generation test. These results suggest a possibly increased coagulation potential in patients with "hyperstimulation syndrome" but not in those receiving the low dosage regimens of human gonadotropins more commonly used for ovarian stimulation at the present time.
D001777:Blood Coagulation / Q000187:drug effects*; D001779:Blood Coagulation Factors / Q000096:biosynthesis*; D001780:Blood Coagulation Tests; D006063:Chorionic Gonadotropin / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D004967:Estrogens / Q000378:metabolism; D005165:Factor V / Q000096:biosynthesis; D005260:Female; D005340:Fibrinogen / Q000096:biosynthesis; D005342:Fibrinolysis / Q000187:drug effects*; D006062:Gonadotropins / Q000494:pharmacology*; D006065:Gonadotropins, Pituitary / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy; D008539:Meigs Syndrome / Q000097:blood* / Q000139:chemically induced; D008596:Menotropins / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D011372:Progestins / Q000378:metabolism; D013925:Thromboplastin / Q000096:biosynthesis; D013927:Thrombosis / Q000209:etiology; D013997:Time Factors
D001779:Blood Coagulation Factors; D006063:Chorionic Gonadotropin; D004967:Estrogens; D006062:Gonadotropins; D006065:Gonadotropins, Pituitary; D011372:Progestins; D008596:Menotropins; D005165:Factor V; D005340:Fibrinogen; D013925:Thromboplastin